RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
Provided By PR Newswire
Last update: Jul 1, 2025
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation
Read more at prnewswire.com1.5
-0.07 (-4.46%)
Find more stocks in the Stock Screener
RDHL Latest News and Analysis
